How immune cells in lymph nodes compete to help make strong HIV antibodies
Revealing the Biophysics of the Germinal Center Microenvironment
Researchers are learning how rare antibody-making B cells compete inside lymph nodes so future HIV vaccines can teach the immune system to make stronger, broadly protective antibodies for people at risk of HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-11237143 on NIH RePORTER |
What this research studies
This project uses mice engineered with human antibody genes to watch how rare precursor B cells behave inside germinal centers (the immune system's antibody factories) after vaccination. The team varies vaccine antigen strength, multivalency, and the starting frequency of those rare B cells to see which conditions let them succeed instead of being outcompeted. They track B cell competition, affinity maturation, and germinal center dynamics with cellular and molecular measurements. The goal is to use those lessons to design vaccine strategies that steer the immune response toward broadly neutralizing antibodies against HIV.
Who could benefit from this research
Good fit: This is laboratory research that does not enroll patients, but the findings are intended to benefit people at risk for HIV and future HIV vaccine trial participants.
Not a fit: People seeking immediate clinical treatments or current HIV therapies will not receive direct, immediate benefit from this basic immunology research.
Why it matters
Potential benefit: If successful, this work could guide HIV vaccine designs that reliably prompt the immune system to produce broadly neutralizing antibodies and lower the chance of infection.
How similar studies have performed: Related preclinical work using VRC01-class models has shown rare precursor B cells can be primed under specific conditions, but no vaccine has yet reliably induced broadly neutralizing antibodies in people.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Abbott, Robert Koehler — University of Texas Med Br Galveston
- Study coordinator: Abbott, Robert Koehler
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.